OptiBiotix Health PLC Launch of LPLDL® product with AlfaSigma
27 Enero 2020 - 1:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
27 January 2020
27 January 2020
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Launch of LP(LDL) (R) product with AlfaSigma
ProBiotix Health, a fully-owned subsidiary of OptiBiotix Health
plc (AIM: OPTI), a life sciences business developing compounds to
tackle obesity, high cholesterol, diabetes and skin care,
communicate that ALFASIGMA S.p.A. ("ALFASIGMA") has recently
announced the launch of a food supplement containing the
cholesterol reducing LP(LDL) (R) probiotic strain developed by
ProBiotix Health. ALFASIGMA will market this first of its kind
nutraceutical probiotic in Italy for cholesterol reduction. This
agreement follows on from the announcement (RNS: 21 June 2018) that
OptiBiotix had entered into license agreement with "ALFASIGMA" to
exclusively commercialise food supplements containing OptiBiotix's
cholesterol and blood pressure reducing LP(LDL) (R) strain in
Italy.
ALFASIGMA, is a multinational pharmaceutical company with 2018
revenues in excess of EUR1 billion and around 3000 employees
globally. Whilst Italy is its core market, ALFASIGMA is present in
more than 90 countries through distributors and subsidiaries.
The launch is being supported by an extensive marketing campaign
aimed at General Practitioners, cardiologist, and pharmacists, to
promote treatment of at risk patients using a natural,
scientifically formulated, food supplement. Italy is the largest
probiotic supplement market in Europe, and the second largest
market in the world, with an estimated >$500 million probiotic
supplements market, and a 25% per annum growth forecast to
2021*.
*Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING
THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June
2017).
Stephen Prescott, Chief Executive of ProBiotix Health,
commented: "We are pleased to communicate the launch of a new
product developed by one of the largest pharmaceutical companies in
Italy and containing our cholesterol reducing probiotic, LPLDL(R).
Italy is the largest and fastest growing probiotic market in Europe
and we are pleased to partner with a company with such a strong
track record in food supplements and pharmaceuticals for
cardiovascular health. The launch of this product is another step
in establishing LP(LDL) (R) as a global probiotic brand. This
agreement is another step in building ProBiotix Health into a
profitable business in 2020."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 20 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
About Alfasigma - www.alfasigma.com
Alfasigma is a leading Italian pharmaceutical company, present
in more than 90 countries, with a workforce of more than 3,000
people and 5 manufacturing plants around the world. More than 44%
of Alfasigma turnover comes from internally developed proprietary
products, one of which is XIFAXAN. More information is available at
the Alfasigma website at: http://www.alfasigma.com/en
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABLGDBLSDDGGS
(END) Dow Jones Newswires
January 27, 2020 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024